MARKSANS PHARMA LIMITED Financial Ratios
MARKSANS · Healthcare · Current price ₹311
P/E ratio
33.7x
P/B ratio
5.0x
ROE
13.8%
ROCE
17.4%
Debt / Equity
0.11
Dividend yield
0.3%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 33.7x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 5.0x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 13.8% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 17.4% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.11 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with MARKSANS PHARMA LIMITED's latest numbers.
MARKSANS PHARMA LIMITED profitability
MARKSANS PHARMA LIMITED generates a return on equity of 13.8% and a return on capital employed of 17.4%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.11 and a P/E of 33.7x, MARKSANS PHARMA LIMITED is conservatively financed. Our overall business-quality score for the company is 5.5 / 10.
Understand the ratios
More on MARKSANS PHARMA LIMITED
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.